Dimethylcurcumin liposome as well as preparation method and application thereof
The dimethyl curcumin liposome prepared by thin-film dispersion method solves the stability and water solubility of dimethyl curcumin in vivo use, improves its bioavailability and targeting effect on tumor cells, and achieves the Better clinical application effects.
Patent Information
- Application Number
- CN202410989077.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Dimethyl curcumin has problems such as poor stability, poor water solubility and low bioavailability when used in vivo, which affects its clinical application.
Dimethyl curcumin liposomes were prepared by thin-film dispersion method, using dimethyl curcumin, phospholipids, cholesterol and lyophilized protective agent as raw materials, and evaporation with rotary reduced pressure and sonication to form a small particle size and high drug loading. amount of liposomes to improve their water solubility and bioavailability.
It effectively overcomes the problems of poor water solubility and low bioavailability of dimethyl curcumin, improves its targeting effect and killing effect on tumor cells, and enhances the stability and biocompatibility of the drug.
Smart Images

Figure CN118903013A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug delivery systems, and in particular relates to a dimethylcurcumin liposome and a preparation method and application thereof. Background Art
[0002] Curcumin (Cur) is a diketone compound extracted from the rhizomes of some plants in the Zingiberaceae and Araceae families. It is an orange-yellow crystalline powder with a slightly bitter taste. It is insoluble in water, soluble in ethanol, and soluble in solvents such as DMSO, DMF, and PEG400. Clinical studies have shown that curcumin has multiple pharmacological effects, including antibacterial, antioxidant, antiviral, anti-inflammatory, anti-Alzheimer's disease, and anti-cancer. Dimethylcurcumin (DMC) is a derivative of curcumin and has higher anticancer activity than curcumin. It can better inhibit cancer cell proliferation, induce cancer cell apoptosis, and inhibit cancer cell transformation.
[0003] It is reported that dimethyl curcumin can enhance the degradation of androgen receptor (AR) in certain cell types, thereby inhibiting the proliferation of cancer cells. In prostate cancer cells, dimethyl curcumin can inhibit AR-related signaling pathways by degrading full-length AR, AR-v7, and AR mutant AR-f876l, thereby inhibiting tumor proliferation. At present, although dimethyl curcumin has significant inhibitory activity against prostate cancer and liver cancer, dimethyl curcumin has problems such as poor stability, poor water solubility, and low bioavailability when used in vivo, which seriously affects the clinical application of dimethyl curcumin. Summary of the invention
[0004] The purpose of the embodiment of the present invention is to provide a dimethylcurcumin liposome to overcome the problems of poor water solubility and low bioavailability of dimethylcurcumin.
[0005] To achieve the above object, the technical solution adopted by the present invention is: to provide a dimethylcurcumin liposome, which is prepared from the following ingredients: dimethylcurcumin, phospholipids, cholesterol and a lyophilization protective agent; wherein the mass ratio of the phospholipids to the cholesterol is (10-1):1, and the mass ratio of the dimethylcurcumin, the cholesterol and the lyophilization protective agent is 3:10:75.
[0006] Preferably, the phospholipid is soybean lecithin.
[0007] Preferably, the lyophilization protective agent is at least one of trehalose, glucose, mannitol and sucrose.
[0008] Another object of the embodiment of the present invention is to provide a dimethylcurcumin liposome preparation to overcome the problems of poor water solubility and low bioavailability of dimethylcurcumin.
[0009] To achieve the above object, the technical solution adopted by the present invention is: to provide a method for preparing dimethylcurcumin liposomes, comprising the following steps:
[0010] Step S01: weighing soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent as raw materials according to a predetermined mass ratio;
[0011] Step S02: placing the soybean lecithin, the cholesterol and the dimethyl curcumin in a container, adding an organic solvent for ultrasonic dissolution, and obtaining a mixed solution;
[0012] Step S03: the mixed solution is subjected to rotary evaporation under reduced pressure in a constant temperature water bath until the organic solvent is completely volatilized, and then dried to obtain a solid mixture;
[0013] Step S04: adding distilled water containing a lyoprotectant to the solid mixture, rotating emulsifying at room temperature and pressure, ultrasonically treating with an ultrasonic instrument, and then sequentially extruding through a membrane, transferring to a freeze dryer to freeze-dry in the dark, and obtaining dimethyl curcumin liposome lyophilized powder.
[0014] Preferably, in the step S01, the mass ratio of the dimethyl curcumin, the soy lecithin, the cholesterol and the lyoprotectant is 3:(100-10):10:75.
[0015] Preferably, in step S02, the organic solvent is anhydrous ethanol.
[0016] Preferably, in step S02, the capacity of the container is 100 mL, and the volume of the organic solvent is 10-20 mL.
[0017] Preferably, in the step S04, the film is a polycarbonate film.
[0018] Preferably, in step S04, the ultrasound instrument is a probe ultrasound instrument.
[0019] Compared with the prior art, the one or more technical solutions in the embodiments of the present invention have at least one of the following beneficial effects:
[0020] The dimethyl curcumin liposomes in the embodiment of the present invention are prepared from dimethyl curcumin, phospholipids, cholesterol and lyophilization protective agents as raw materials, and have a small particle size, a high drug loading and excellent lyophilization and resolubility performance, effectively overcoming the problems of poor water solubility and low bioavailability of dimethyl curcumin. In addition, the dimethyl curcumin liposome preparation method in the embodiment of the present invention adopts the dimethyl curcumin liposomes prepared by the thin film dispersion method, and dimethyl curcumin can be encapsulated in the liposomes, which is conducive to improving the water solubility of dimethyl curcumin. In addition, the particle size of the dimethyl curcumin liposomes is small, and it is easy to be taken up by tumor cells, which can enhance the targeting effect and killing effect on tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0022] Figure 1 This is a particle size distribution diagram of the dimethylcurcumin liposomes prepared in Example 1 of the present invention. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0024] Example 1
[0025] Dimethyl curcumin liposomes were prepared by thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to a predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 700 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 20 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing trehalose was added. After rotation emulsification at room temperature and pressure, a probe ultrasonic instrument was used for ultrasonic treatment, and then polycarbonate membranes were sequentially passed, and the mixture was moved to a freeze dryer to avoid light and freeze-dried to obtain dimethyl curcumin liposome lyophilized powder.
[0026] Example 2
[0027] Dimethyl curcumin liposomes were prepared by thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to a predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 700 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 15 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing trehalose was added. After rotation emulsification at room temperature and pressure, a probe ultrasonic instrument was used for ultrasonic treatment, and then polycarbonate membranes were sequentially passed, and the mixture was moved to a freeze dryer to avoid light and freeze-dried to obtain dimethyl curcumin liposome lyophilized powder.
[0028] Example 3
[0029] The dimethyl curcumin liposomes were prepared by a thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to a predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 700 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 10 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing trehalose was added. After rotational emulsification at room temperature and pressure, a probe ultrasonic instrument was used for ultrasonic treatment, and then polycarbonate membranes were sequentially passed, and the mixture was moved to a freeze dryer to avoid light and freeze-dried to obtain a dimethyl curcumin liposome freeze-dried powder.
[0030] Example 4
[0031] The dimethyl curcumin liposomes were prepared by a thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to a predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 100 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 20 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing trehalose was added. After rotational emulsification at room temperature and pressure, a probe ultrasonic instrument was used for ultrasonic treatment, and then polycarbonate membranes were sequentially passed, and the mixture was moved to a freeze dryer to avoid light and freeze-dried to obtain a lyophilized dimethyl curcumin liposome powder.
[0032] Example 5
[0033] Dimethyl curcumin liposomes were prepared by thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to a predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 300 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 20 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing trehalose was added. After rotation emulsification at room temperature and pressure, a probe ultrasonic instrument was used for ultrasonic treatment, and then polycarbonate membranes were sequentially passed, and the mixture was moved to a freeze dryer to avoid light and freeze-dried to obtain dimethyl curcumin liposome lyophilized powder.
[0034] Example 6
[0035] Dimethyl curcumin liposomes were prepared by thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to a predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 1000 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 20 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing trehalose was added. After rotational emulsification at room temperature and pressure, a probe ultrasonic instrument was used for ultrasonic treatment, and then polycarbonate membranes were sequentially passed, and the mixture was moved to a freeze dryer to avoid light and freeze-dried to obtain dimethyl curcumin liposome lyophilized powder.
[0036] Example 7
[0037] Dimethyl curcumin liposomes were prepared by thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to the predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 700 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 20 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing glucose was added. After rotary emulsification at room temperature and pressure, a probe ultrasonic instrument was used for ultrasonic treatment, and then the polycarbonate membrane was passed in turn, and the mixture was moved to a freeze dryer to freeze-dry in the dark to obtain a lyophilized powder of dimethyl curcumin liposomes.
[0038] Example 8
[0039] Dimethyl curcumin liposomes were prepared by thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to the predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 700 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 20 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing mannitol was added. After rotational emulsification at room temperature and pressure, ultrasonic treatment was performed using a probe ultrasonic instrument, and then successively passed through a polycarbonate membrane, and moved to a freeze dryer to freeze dry in the dark to obtain a lyophilized powder of dimethyl curcumin liposomes.
[0040] Example 9
[0041] Dimethyl curcumin liposomes were prepared by thin film dispersion method, and soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent were weighed as raw materials according to a predetermined mass ratio, wherein dimethyl curcumin 30 mg, soybean lecithin 700 mg, and cholesterol 100 mg. Soybean lecithin, cholesterol, and dimethyl curcumin were dissolved in 20 mL of anhydrous ethanol, and the anhydrous ethanol was evaporated by rotation under reduced pressure in a constant temperature water bath to form a uniform lipid film, which was placed in a vacuum drying oven for drying, and distilled water containing sucrose was added. After rotation emulsification at room temperature and pressure, a probe ultrasonic instrument was used for ultrasonic treatment, and then polycarbonate membranes were sequentially passed, and the mixture was moved to a freeze dryer to avoid light and freeze-dried to obtain dimethyl curcumin liposome lyophilized powder.
[0042] Comparative Example 1
[0043] Dimethyl curcumin liposomes were prepared by thin film dispersion method. 30 mg of dimethyl curcumin and 700 mg of soybean lecithin were dissolved in 20 mL of anhydrous ethanol, and the mixture was evaporated under reduced pressure in a constant temperature water bath until the anhydrous ethanol was evaporated to form a uniform lipid film, which was then dried in a vacuum drying oven. Distilled water containing trehalose was added, and the mixture was emulsified by rotation at room temperature and pressure, and then ultrasonicated using a probe ultrasonic instrument. The mixture was then passed through a polycarbonate membrane in sequence, and then transferred to a freeze dryer to be freeze-dried in the dark to obtain lyophilized dimethyl curcumin liposome powder.
[0044] Comparative Example 2
[0045] Dimethyl curcumin liposomes were prepared by thin film dispersion method. 30 mg dimethyl curcumin, 700 mg soybean lecithin and 100 mg cholesterol were dissolved in 20 mL anhydrous ethanol, and the mixture was evaporated in a constant temperature water bath under reduced pressure until the anhydrous ethanol was evaporated to form a uniform lipid film, which was then dried in a vacuum drying oven. Distilled water was then added, and the mixture was emulsified by rotation at room temperature and pressure, and then ultrasonicated using a probe ultrasonic instrument. The mixture was then passed through a polycarbonate membrane in sequence, and then transferred to a freeze dryer to be freeze-dried in the dark to obtain lyophilized dimethyl curcumin liposome powder.
[0046] Test Example 1
[0047] Determination of particle size and potential of dimethylcurcumin liposomes
[0048] Preparation of test solution: The dimethylcurcumin liposome freeze-dried powder prepared in Examples 1 to 9 and Comparative Examples 1 to 2 was added to ultrapure water, and ultrasonically dispersed for 5 minutes to prepare 1 mg / ml liposome dispersions.
[0049] Particle size and potential measurement: Take 1 ml of each of the above-prepared nanoparticle dispersions and measure the particle size and potential using a Malvern particle size analyzer.
[0050] The particle size distribution of dimethylcurcumin liposomes prepared in Example 1 is as follows: Figure 1 As shown. The experimental results show that in Examples 1 to 9 and Comparative Examples 1 to 2, the particle size and charge characterization of the dimethylcurcumin liposomes prepared in Example 1 are better, the particle size is normally distributed, the particle size distribution is narrow, and the average diameter is about 100nm, which is conducive to long blood circulation and tumor targeting; the polydispersity index is about 0.3, indicating a narrow particle size distribution. In addition, the Zeta potential of the dimethylcurcumin liposomes prepared in Example 1 is negative, which is conducive to long blood circulation.
[0051] Table 1 Particle size and potential test table of dimethylcurcumin liposomes in Examples 1 to 9 and Comparative Examples 1 to 2
[0052] sample Particle size (nm) Polydispersity index Zeta potential (mV) Example 1 110.67±0.83 0.340±0.026 -1.211±0.080 Example 2 312.38±0.37 0.674±0.092 -0.983±0.094 Example 3 586.25±0.93 0.915±0.481 -0.304±0.163 Example 4 421.33±0.45 0.79±0.586 -1.532±0.011 Example 5 173.28±2.68 0.431±0.028 -4.523±0.068 Example 6 156.02±1.80 0.427±0.027 -2.497±0.162 Example 7 185.29±1.52 0.453±0.001 -4.980±0.2868 Example 8 248.03±11.21 0.621±0.113 -4.810±0.185 Example 9 218.50±16.29 0.473±0.051 -0.751±0.121 Comparative Example 1 591.27±3.64 0.831±0.327 -0.469±0.251 Comparative Example 2 1049.48±12.50 0.992±0.153 -0.352±0.467
[0053] Test Example 2
[0054] Standard curve fitting of dimethylcurcumin in anhydrous ethanol solution
[0055] Accurately weigh 1.0 mg of dimethyl curcumin reference substance and place it in a 10 mL volumetric flask, dissolve it with anhydrous ethanol and dilute it to the scale, then dilute it with anhydrous ethanol to a series of concentrations (0.25-20 μg / mL) and shake it well, and analyze the dimethyl curcumin content in a multifunctional microplate detector. The detection wavelength of the microplate is 420 nm. With the concentration of dimethyl curcumin as the horizontal coordinate, the unit is μg / ml, and the absorbance as the vertical coordinate, the linear fitting of the dimethyl curcumin standard curve is performed using Origin Pro 2021 software. The regression equation obtained by linear fitting is Y=0.10394X+0.06083(R 2 =0.9977).
[0056] Test Example 3
[0057] Determination of drug loading and encapsulation efficiency of dimethylcurcumin-loaded liposomes
[0058] 3 mg of freeze-dried dimethylcurcumin-loaded liposomes were accurately weighed and dissolved in 6 ml of anhydrous ethanol. The absorbance at 420 nm was measured using a multifunctional microplate reader and substituted into the dimethylcurcumin standard curve to calculate the content of dimethylcurcumin.
[0059] The drug loading calculation formula is:
[0060]
[0061] The encapsulation efficiency calculation formula is:
[0062]
[0063] The drug loading and encapsulation efficiency of the liposomes prepared in Examples 1 to 9 and Comparative Examples 1 to 2 are shown in Table 2. Among Examples 1 to 9 and Comparative Examples 1 to 2, the best drug loading and encapsulation efficiency of the dimethylcurcumin liposomes prepared in Example 1 were 1.53% and 81.21%, respectively.
[0064] Table 2 Drug loading and encapsulation efficiency test table of dimethylcurcumin liposomes in Examples 1 to 9 and Comparative Examples 1 to 2
[0065] sample Drug loading (%) Encapsulation rate (%) Example 1 1.53 81.21 Example 2 1.24 65.17 Example 3 1.02 53.98 Example 4 0.27 19.62 Example 5 0.36 19.10 Example 6 0.30 16.05 Example 7 0.39 20.43 Example 8 0.61 43.14 Example 9 0.28 14.97 Comparative Example 1 0.46 22.77 Comparative Example 2 0.51 13.89
[0066] Test Example 4
[0067] In vitro simulated drug release evaluation
[0068] Based on the results of Test Examples 1 to 2, the dimethylcurcumin liposomes prepared in Example 1 and Comparative Example 1 were selected for in vitro simulated drug release evaluation.
[0069] Preparation of pH 5.0 release solution: weigh 0.12 g potassium dihydrogen phosphate and 1.79 g disodium hydrogen phosphate dodecahydrate, add 350 ml ultrapure water, 150 ml anhydrous ethanol and 2.5 ml Tween-80 to dissolve, and then adjust the pH to 5.0.
[0070] Preparation of pH 7.4 release solution: weigh 0.12 g potassium dihydrogen phosphate and 1.79 g disodium hydrogen phosphate dodecahydrate, add 350 ml ultrapure water, 150 ml anhydrous ethanol and 2.5 ml Tween-80 to dissolve, and then adjust the pH to 7.4.
[0071] Table 3 Cumulative release test of dimethylcurcumin liposome solution in Example 1 and Comparative Example 1
[0072]
[0073] In vitro simulated drug release evaluation: 1 ml of Example 1 of the present invention is loaded into a dialysis bag (molecular weight cutoff: 3500), sealed, then immersed in 30 ml of the release solution of the above configuration, placed in a shaking table for vibration, the temperature is 37 ° C, the speed is 180 rpm. Take out 1 ml of the release solution at 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, and 96 hours, respectively, and then add 1 ml of the corresponding blank release solution. The release experiment in each release solution is parallel to three groups. The release experiment is carried out under the condition of luminescence. The release solution taken out is calculated by detecting the absorbance to calculate the cumulative release of dimethyl curcumin. The cumulative release of dimethyl curcumin liposome solution prepared by Example 1 and Comparative Example 1 is shown in Table 3.
[0074] As shown in Table 3, Example 1 has similar drug release behavior in release media of pH 7.4 and pH 5.0. Among them, the release of Example 1 is slow release, and only about 24% of dimethyl curcumin is released within 48 hours. In addition, the cumulative release of Example 1 in pH 7.4 and pH 5.0 release media for 72h is 30.46% and 24.80%, respectively. The slower release rate is conducive to the stability of dimethyl curcumin, and the release behavior of dimethyl curcumin under different pH conditions does not change significantly, which shows that Example 1 has no pH responsiveness. However, the release rate of Comparative Example 1 is slow and the total amount of release is small in the release media of pH 7.4 and pH 5.0, and the total amount of release is only 4.97% and 5.11%.
[0075] Test Example 5
[0076] Prostate cancer cell uptake assessment
[0077] Based on the results of Experimental Examples 1 and 2, the dimethylcurcumin liposomes prepared in Example 1 and Comparative Example 1 were selected for evaluation of prostate cancer cell uptake.
[0078] Preparation of test solution: The dimethyl curcumin liposome lyophilized powder prepared in Example 1 and Comparative Example 1 was dissolved in ultrapure water, and a dimethyl curcumin concentration of 10 μg / ml nanoparticle test solution was prepared in RPMI1640 medium (containing 10% fetal bovine serum and 1% penicillin & streptomycin), and the same concentration of free dimethyl curcumin was used as a control group.
[0079] Evaluation of cell uptake: 22Rv1 prostate cancer cells were seeded in 12-well plates at a density of 100,000 cells per well, cultured overnight to adhere to the plate, and then the culture medium was replaced with the above-prepared test solutions (n=3), and cultured in a cell culture incubator at 37°C for 6 hours. The culture medium was then aspirated, and the cells were washed three times with phosphate buffer (pH7.4, 6.7mM), 0.5 ml of trypsin was added to digest the cells, and 2 ml of RPMI1640 culture medium (containing 10% fetal bovine serum and 1% penicillin & streptomycin) was added to terminate the digestion. The cells were centrifuged for 5 minutes (1000 rpm), the supernatant was aspirated, and the cells were blown away with 1 ml of phosphate buffer (pH 7.4, 6.7mM), and the uptake was detected by flow cytometry.
[0080] 22Rv1 prostate cancer cells were seeded in a confocal dish at a density of 100,000 cells per well, cultured overnight to adhere to the wall, and then the culture medium was replaced with the above-prepared test solutions, cultured in a cell culture incubator at 37°C for 6 hours, washed three times with phosphate buffer (pH 7.4, 6.7mM), and fixed with 1 ml of 4% paraformaldehyde at room temperature in the dark for 20 minutes, washed three times with phosphate buffer (pH 7.4, 6.7mM), then 600 μl of 4,6-diamino-2-phenylindole solution (5 μg per ml) was added to the confocal dish and incubated for 15 minutes, washed three times with phosphate buffer (pH 7.4, 6.7mM), and the fluorescence image was observed with a confocal microscope.
[0081] The cell flow cytometry results of Example 1 and Comparative Example 1 are shown in Table 4. The flow cytometer detection results show that after 22Rv1 cells were incubated with each liposome test solution for 6 hours, the cell uptake of Example 1 was about 1.9 times the uptake of free dimethylcurcumin, and the cell uptake of Comparative Example 1 was about 1.1 times the uptake of free dimethylcurcumin, indicating that Example 1 has a better prostate cancer cell targeting effect.
[0082] The cell confocal results of Example 1 showed that the green fluorescence intensity observed in the cytoplasm of Example 1 was stronger than that of free dimethyl curcumin and Comparative Example 1, indicating that Example 1 has the ability to enhance cellular uptake compared with free dimethyl curcumin.
[0083] Table 4 Cellular uptake test of dimethylcurcumin liposomes and free dimethylcurcumin in 22Rv1 cells in Example 1 and Comparative Example 1
[0084] sample Relative cellular uptake Free dimethylcurcumin 1.00±0.21 Example 1 1.93±0.72 Comparative Example 1 1.13±0.35
[0085] Test Example 6
[0086] In vitro toxicity test
[0087] Based on the results of Experimental Examples 1 and 2, the dimethylcurcumin liposomes prepared in Example 1 and Comparative Example 1 were selected for in vitro toxicity test. HepG2 and 22Rv1 cells were cultured at 5×10 3 The cells were inoculated into a 96-well plate at a density of 10 cells per well, and 5 parallel experiments were performed for each concentration. Free dimethylcurcumin, Example 1 and Comparative Example 1 were diluted with corresponding complete culture medium into a series of concentrations (the concentrations were 1 μg / mL, 2 μg / mL, 5 μg / mL, 10 μg / mL, 15 μg / mL, and 20 μg / mL, respectively) and added to a 96-well plate, and incubated with HepG2 and 22Rv1 cells for 24 h and 48 h, respectively, and then the culture medium was removed, and 150 μL DMSO was further added to each well to fully dissolve the formazan generated by MTT reduction, and the absorbance at 490 nm was detected in a multifunctional microplate detector, and the cells incubated with blank culture medium were taken as 100% survival rate.
[0088] In all cell lines, they all showed dose- and time-dependent cytotoxicity. The IC50 data of free dimethyl curcumin, Example 1 and Comparative Example 1 for 22Rv1 and HepG2 cells are shown in Table 5. For 22Rv1 and HepG2 cells, the cytotoxicity of Example 1 is stronger than that of free dimethyl curcumin and Comparative Example 1. After Example 1 (20 μg / mL DMC) treated HepG2 cells for 24 hours, the cell viability was less than 40%, while after free dimethyl curcumin and Comparative Example 1 (20 μg / mL) treated HepG2 cells for 24 hours, the cell viability was greater than 80%. When free dimethyl curcumin, Example 1 and Comparative Example 1 (10 μg / mL DMC) were incubated with 22Rv1 cells for 24 hours, the cell survival rates were 85%, 81% and 50%, respectively. The results of the cytotoxicity test showed that the IC50 of Example 1 was significantly reduced compared with free dimethyl curcumin and Comparative Example 1, indicating that the in vitro antitumor effect of Example 1 on HepG2 and 22Rv1 cells was significantly enhanced. Therefore, the good in vitro antitumor effect of Example 1 is related to its improved water solubility and cellular uptake of dimethyl curcumin.
[0089] Table 5 In vitro toxicity test table of dimethyl curcumin liposomes and free dimethyl curcumin in Example 1 and Comparative Example 1
[0090]
[0091] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A dimethylcurcumin liposome, It is characterized in that The invention is prepared from the following ingredients: dimethyl curcumin, phospholipid, cholesterol and freeze-drying protective agent; wherein the mass ratio of the phospholipid to the cholesterol is (10-1):1, and the mass ratio of the dimethyl curcumin, the cholesterol and the freeze-drying protective agent is 3:10:
75.
2. The dimethylcurcumin liposome according to claim 1, It is characterized in that The phospholipid is soybean lecithin.
3. The dimethylcurcumin liposome according to claim 1, It is characterized in that The freeze-drying protective agent is at least one of trehalose, glucose, mannitol and sucrose.
4. A method for preparing dimethylcurcumin liposomes, It is characterized in that The steps include: Step S01: weighing soybean lecithin, cholesterol, dimethyl curcumin and lyophilization protective agent as raw materials according to a predetermined mass ratio; Step S02: placing the soybean lecithin, the cholesterol and the dimethyl curcumin in a container, adding an organic solvent for ultrasonic dissolution, and obtaining a mixed solution; Step S03: the mixed solution is subjected to rotary evaporation under reduced pressure in a constant temperature water bath until the organic solvent is completely volatilized, and then dried to obtain a solid mixture; Step S04: adding distilled water containing a lyoprotectant to the solid mixture, rotating emulsifying at room temperature and pressure, ultrasonically treating with an ultrasonic instrument, and then sequentially extruding through a membrane, transferring to a freeze dryer to freeze-dry in the dark, and obtaining dimethyl curcumin liposome lyophilized powder.
5. The method for preparing dimethylcurcumin liposomes as claimed in claim 4, It is characterized in that In the step S01, the mass ratio of the dimethyl curcumin, the soybean lecithin, the cholesterol and the lyophilization protective agent is 3:(100-10):10:
75.
6. The method for preparing dimethylcurcumin liposomes as claimed in claim 4, It is characterized in that In the step S02, the organic solvent is anhydrous ethanol.
7. The method for preparing dimethylcurcumin liposomes as claimed in claim 4, It is characterized in that In the step S02, the capacity of the container is 100 mL, and the volume of the organic solvent is 10-20 mL.
8. The method for preparing dimethylcurcumin liposomes as claimed in claim 4, It is characterized in that In the step S04, the film is a polycarbonate film.
9. The method for preparing dimethylcurcumin liposomes as claimed in claim 4, It is characterized in that In step S04, the ultrasound instrument is a probe ultrasound instrument.
10. Use of the dimethylcurcumin liposome according to any one of claims 1 to 3 or the dimethylcurcumin liposome prepared by the method for preparing the dimethylcurcumin liposome according to any one of claims 4 to 9 in treating antitumor drugs.
Citation Information
Patent Citations
Preparation of water-soluble dimethyl curcumin liposome fluorescent probe and detection method of water-soluble dimethyl curcumin liposome fluorescent probe
CN108822831A
Applications of liposome dimethylcurcumin in inhibition of rat splenic lymphocyte propagation and adjusting cell cycle
CN108992404A
Liposome dimethylcurcumin inhibits activities of dipeptidase I and matrix metalloproteinase-9
CN109223738A
Dimethyl curcumin prodrug nanoparticles, nano preparation and preparation method and application of prodrug nanoparticles
CN111973756A
Drug-loaded crocin nanoparticles and preparation method thereof
CN118141768A
Cited By
Polyethylene glycol liposome loaded with dimethyl curcumin and preparation method thereof
CN119868273A
Polyethylene glycol-modified liposomes loaded with dimethylcurcumin and their preparation method
CN119868273B
